• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ASP Isotopes Announces Purchase Order for Enriched Barium-137 from a U.S.-Based Customer

    9/30/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials
    Get the next $ASPI alert in real time by email

    WASHINGTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has received a purchase order from a U.S.-based customer for the supply of enriched Barium-137, with a delivery date during Q1 2026.

    Enriched Barium-137: Unlocking Scalable Quantum Computing

    The use of high-purity Barium-137 is emerging as a critical enabler of ion-trap quantum computing, one of the leading approaches to building large-scale quantum machines.

    By providing a stable and uniform qubit platform, enriched Barium-137 allows for more reliable operation of quantum processors and reduces the complexity of control systems. This improved consistency is essential for scaling from today's small research systems to tomorrow's fault-tolerant quantum computers capable of solving real-world problems.

    In addition, Barium-137's favourable optical properties—operating in accessible visible-light wavelengths—make it easier to integrate with existing hardware and support future developments in quantum networking and modular architectures, where multiple processors are linked together to create more powerful systems.

    As demand for larger, commercially viable quantum computers accelerates across industries, enriched Barium-137 is expected to become a cornerstone material, helping to bridge the gap between laboratory demonstrations and practical, scalable technologies.

    Robert Ainscow, Interim CEO of ASP Isotopes, commented:

    "This purchase order for enriched Barium-137 is an important achievement in our strategy to establish ASP Isotopes as a leading supplier of advanced materials to the quantum computing industry. We anticipate growing demand from customers as enriched Barium-137 has the potential to be transformative in enabling scalable architectures. We believe we have the ability to reliably produce and deliver multiple industrial isotopes, such as Barium-137 and Silicon-28. We are excited about the role ASP Isotopes can play in supporting cutting-edge technologies and advancing quantum computing from the laboratory into real-world commercial applications."

    Viktor Petkov, Chief Commercial Officer of ASP Isotopes, added:

    "This purchase order for enriched Barium-137 is a testament to how our products align with ASP Isotopes' broader multi-isotope, multi-use, multi-customer electronic gases strategy. This sector is rapidly evolving into one of the most dynamic and significant growth markets in advanced materials. Demand for isotopically pure gases and materials now spans quantum computing, semiconductors, AI capability, data center construction and a wide range of other high-technology applications. By positioning ourselves at the centre of this expanding supply chain, ASP Isotopes is building a scalable business model capable of serving multiple industries while supporting the breakthrough technologies that will shape the future."

    About ASP Isotopes Inc.

    ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process ("ASP technology"). The Company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).

    There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. We believe the ASP technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.

    Forward Looking Statements

    This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as "believes," "plans," "anticipates," "expects," "estimates," "projects," "will," "may," "might," and words of a similar nature. Examples of forward-looking statements include, among others but are not limited to, the commencement of supply of isotopes to customers, the construction of additional enrichment facilities, and statements we make regarding expected operating results, such as future revenues and prospects from the potential commercialization of isotopes, future performance under contracts, and our strategies for product development, engaging with potential customers, market position, and financial results. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including, but not limited to: the failure to obtain necessary regulatory and shareholder approvals for the proposed acquisition of Renergen; disruption from the proposed acquisition of Renergen making it more difficult to maintain business and operational relationships; significant transaction costs and unknown liabilities related to the proposed acquisition of Renergen; litigation or regulatory actions related to the proposed acquisition of Renergen; the outcomes of various strategies and projects undertaken by the Company; the potential impact of laws or government regulations or policies in South Africa, the United Kingdom or elsewhere; our reliance on the efforts of third parties; our future capital requirements and sources and uses of cash; our ability to obtain funding for our operations and future growth; our reliance on the efforts of third parties; our ability to complete the construction and commissioning of our enrichment plants or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part I, Item 1A. "Risk Factors" of the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and any amendments thereto and in the company's subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. This press release includes market and industry data and forecasts that we obtained from internal research, publicly available information and industry publications and surveys. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Unless otherwise noted, statements as to our potential market position relative to other companies are approximated and based on third-party data and internal analysis and estimates as of the date of this press release. We have not independently verified this information, and it could prove inaccurate. Industry and market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data-gathering process and other limitations and uncertainties. In addition, we do not know all of the assumptions regarding general economic conditions or growth that were used in preparing the information and forecasts from sources cited herein. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.

    Contacts

    Jason Assad– Investor relations

    Email: [email protected]

    Telephone: 561-709-3043



    Primary Logo

    Get the next $ASPI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASPI

    DatePrice TargetRatingAnalyst
    10/4/2024$4.50Buy
    Canaccord Genuity
    12/5/2023$3.25Buy
    H.C. Wainwright
    More analyst ratings

    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Ainscow Robert sold $71,945 worth of shares (8,438 units at $8.53), exercised 297,000 shares at a strike of $1.12 and covered exercise/tax liability with 38,861 shares, increasing direct ownership by 18% to 1,669,693 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    9/10/25 9:01:09 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Chief Executive Officer Mann Paul Elliot sold $1,371,531 worth of shares (162,153 units at $8.46), exercised 1,216,000 shares at a strike of $2.00 and covered exercise/tax liability with 285,110 shares, increasing direct ownership by 11% to 8,084,191 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    9/10/25 9:00:31 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Director Moore Duncan sold $696,232 worth of shares (75,000 units at $9.28), decreasing direct ownership by 7% to 994,553 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    9/3/25 5:40:33 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    SEC Filings

    View All

    ASP Isotopes Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    9/30/25 10:56:31 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    9/29/25 11:08:52 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. filed SEC Form 8-K: Other Events

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    9/22/25 8:38:08 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on ASP Isotopes with a new price target

    Canaccord Genuity initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $4.50

    10/4/24 7:13:36 AM ET
    $ASPI
    Major Chemicals
    Industrials

    H.C. Wainwright initiated coverage on ASP Isotopes with a new price target

    H.C. Wainwright initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $3.25

    12/5/23 7:36:42 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Ainscow Robert bought 19,992 shares, increasing direct ownership by 2% to 919,992 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:49 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Chief Executive Officer Mann Paul Elliot bought 39,984 shares, increasing direct ownership by 0.69% to 5,845,627 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:33 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Large owner Ak Jensen Investment Management Ltd bought $515,088 worth of shares (161,849 units at $3.18) (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/10/24 5:59:47 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ASP Isotopes Announces Purchase Order for Enriched Barium-137 from a U.S.-Based Customer

    WASHINGTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has received a purchase order from a U.S.-based customer for the supply of enriched Barium-137, with a delivery date during Q1 2026. Enriched Barium-137: Unlocking Scalable Quantum Computing The use of high-purity Barium-137 is emerging as a critical enabler of ion-trap quantum computing, one of the leading approaches to building large-scale quantum machines. By providing a stable and uniform qubit platfo

    9/30/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. Announces Changes to the Executive Management Teams of ASP Isotopes Inc. and Quantum Leap Energy LLC Effective October 2025

    - ASP Isotopes Inc. appoints Interim CEO as Paul Mann becomes Executive Chairman. - Quantum Leap Energy LLC appoints Michael Cunniffe as CFO. - ASP Isotopes Inc. provides information on upcoming investor events. WASHINGTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that, effective October 1, 2025, Paul Mann, the founder, Chairman and Chief Executive Officer of ASP Isotopes, will become Executive Chairman of ASP Isotopes and will be taking a tempora

    9/29/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Nuclear Power Industry Veteran Ralph Hunter Joins Board of Directors of ASP Isotopes Inc. and Board of Managers of Quantum Leap Energy LLC

    WASHINGTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Ralph L. Hunter, Jr. to the board of directors of ASP Isotopes and the board of managers of Quantum Leap Energy LLC. Ralph L. Hunter, Jr. has over thirty years' experience in the nuclear power industry in leadership roles spanning strategy, operations, and innovation, and he brings expertise in nuclear technology development and commercialization, energy systems, and market development. Mr. Hun

    9/8/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Leadership Updates

    Live Leadership Updates

    View All

    Nuclear Power Industry Veteran Ralph Hunter Joins Board of Directors of ASP Isotopes Inc. and Board of Managers of Quantum Leap Energy LLC

    WASHINGTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Ralph L. Hunter, Jr. to the board of directors of ASP Isotopes and the board of managers of Quantum Leap Energy LLC. Ralph L. Hunter, Jr. has over thirty years' experience in the nuclear power industry in leadership roles spanning strategy, operations, and innovation, and he brings expertise in nuclear technology development and commercialization, energy systems, and market development. Mr. Hun

    9/8/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Issues Letter to Shareholders

    WASHINGTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and CEO, Paul Mann. Dear Fellow Shareholder, The past few months have been exciting and highly rewarding as the Company has brought three isotope enrichment facilities into operation. I am delighted to report that the Company has now shipped the first samples of both Ytterbium-176 and Silicon-28 to customers, a major milestone for the Company that should allo

    9/2/25 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. Announces Expected Commencement of Dual Listing on Johannesburg Stock Exchange

    WASHINGTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today provided an update on its application to list on the Johannesburg Stock Exchange ("JSE"). The JSE has approved the listing of the Company's common stock on the Main Board of the JSE under the abbreviated name "ASPI", share code "ISO" and international securities identification number US00218A1051, with commencement of trading expected on Wednesday, August 27, 2025. The Company will retain its primary listing on the Nasdaq Cap

    8/8/25 9:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Financials

    Live finance-specific insights

    View All

    ASP Isotopes Inc. Hosts South African Investors in Advance of Secondary Listing on the Johannesburg Stock Exchange (JSE) and Provides Updates on its Isotope Production Plants

    - ASP Isotopes will host an investor access event on Tuesday, August 26, 2025 at its Pretoria facilities for approximately 30 South African investors. - ASP Isotopes expects to have a secondary listing on the Johannesburg Stock Exchange (JSE) and its common stock is expected to commence trading on the JSE on Wednesday, August 27, 2025. - ASP Isotopes has shipped its first samples of enriched Silicon-28 to a US-based customer and expects to complete the enrichment of the first samples of Ytterbium 176 during August 2025. - ASP Isotopes Management Team will feature on a RedChip Investor call at 4:15 pm EDT on Thursday, August 28, 2025. Ryno Pretorius, CEO of Quantum Leap Energy, and Stefano

    8/26/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment

    - IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. - IsoBio has closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. (ASPI). - The strategic collaboration contemplates future manufacturing opportunities for PET Labs (ASPI's nuclear medicine subsidiary). - IsoBio plans to leverage the technology and global manufacturing capabilities developed by ASPI to reduce the uncertainty of isotope supply chain/manufacturi

    7/28/25 8:31:17 AM ET
    $ASPI
    $IMNM
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mobilicom and ASP Isotopes Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / September 13, 2024 / RedChip Companies will air interviews with Mobilicom Ltd. (NASDAQ:MOB) and ASP Isotopes Inc. (NASDAQ:ASPI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 14, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Mobilicom: https://www.redchip.com/assets/access/mob_accessASP Isotopes: https://www.redchip.com/assets/access/aspi_accessOren Elkayam, Founder and CEO of Mobilicom, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Mobilicom presents a

    9/13/24 9:00:00 AM ET
    $ASPI
    $BOXL
    $MOB
    Major Chemicals
    Industrials
    Other Consumer Services
    Real Estate

    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ASP Isotopes Inc.

    SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

    11/14/24 3:01:19 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by ASP Isotopes Inc.

    SC 13G/A - ASP Isotopes Inc. (0001921865) (Subject)

    11/7/24 4:15:14 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by ASP Isotopes Inc.

    SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

    11/3/23 4:15:20 PM ET
    $ASPI
    Major Chemicals
    Industrials